Silvia Calviño Günther1, Carole Schwebel2, Rebecca Hamidfar-Roy2, Agnès Bonadona2, Maxime Lugosi2, Claire Ara-Somohano2, Clémence Minet2, Leïla Potton2, Jean-Charles Cartier2, Aurelien Vésin3, Magalie Chautemps2, Lenka Styfalova2, Stephane Ruckly3, Jean-François Timsit3,4,5. 1. University Hospital of Grenoble Alpes, Medical Intensive Care Unit, Albert Michallon Teaching Hospital, CS10217, 38043, Grenoble Cedex 9, France. SCalvino-gunther@chu-grenoble.fr. 2. University Hospital of Grenoble Alpes, Medical Intensive Care Unit, Albert Michallon Teaching Hospital, CS10217, 38043, Grenoble Cedex 9, France. 3. Albert Bonniot Institute, INSERM U823 "Outcome of Cancer and Critical Illness", 38076, Grenoble, France. 4. Medical and Infectious Diseases Intensive Care Unit, AP-HP, Bichat-Claude Bernard Teaching Hospital, 75018, Paris, France. 5. Inserm Paris-Diderot University-UMR 1137-IAME Team 5-DeSCID: Decision SCiences in Infectious Diseases, Control and Care, Sorbonne Paris Cité, 75018, Paris, France.
Abstract
PURPOSE: To describe all post-insertion complications involving most used intravascular access, and to determine whether the use of a new-generation transparent dressing (3M™ IV Advanced) might reduce their number and impact on ICU patient outcomes. METHODS:Patients older than 18, with an expected length of stay ≥48 h and requiring at least one central venous catheter (CVC), arterial catheter (AC), haemodialysis catheter (HDC), pulmonary arterial catheters (PAC) or peripheral venous catheter (PVC) were randomized into two groups: a new-generation transparent dressing, or the hospital's classical transparent dressing, and were followed daily for any infectious and non-infectious complications. Complications were graduated for severity by an independent international multicentre multidisciplinary panel of practitioners using a Delphi process. RESULTS: We included 628 patients, 2214 catheters (873 PVCs, 630 CVCs, 512 ACs and 199 HDCs and PACs) and 4836 dressings. Overall incidence rate was of 60.9/1000 catheter-days. The most common complication was dysfunction (34.6/1000 catheter-days), mainly for PVCs (16/1000 catheter-days) and ACs (12.9/1000 catheter-days). Infectious complications incidence rate in CVCs and ACs was of 14.5/1000, mostly due to colonization (14.2/1000 catheter-days). Thrombosis incidence was of 3.8/1000 catheter-days with severe and very severe complications in 16 cases (1.8/1000 catheter-days) and one thrombosis-related death. 3M™ IV Advanced dressing did not decrease the rate of catheters with at least a minor complication [57.37/1000 vs. 57.52/1000 catheter-days, HR 1.03, CI (0.84-1.27), p = 0.81]. Incidence rates for each single complication remained equivalent: infectious [HR 0.93 (0.62-1.40), p = 0.72], deep thrombosis [HR 0.90 (0.39-2.06), p = 0.80], extravasation and phlebitis [HR 1.40 (0.69-2.82), p = 0.35], accidental removal [1.07 (0.56-2.04), p = 0.84] and dysfunction [HR 1.04 (0.80-1.35), p = 0.79]. CONCLUSION: The ADVANCED study showed the overall risk of complications to intravascular catheters in ICU patients being dysfunction, infection and thrombosis. The 3M™ IV Advanced dressing did not decrease complication rates as compared to standard dressings.
RCT Entities:
PURPOSE: To describe all post-insertion complications involving most used intravascular access, and to determine whether the use of a new-generation transparent dressing (3M™ IV Advanced) might reduce their number and impact on ICU patient outcomes. METHODS:Patients older than 18, with an expected length of stay ≥48 h and requiring at least one central venous catheter (CVC), arterial catheter (AC), haemodialysis catheter (HDC), pulmonary arterial catheters (PAC) or peripheral venous catheter (PVC) were randomized into two groups: a new-generation transparent dressing, or the hospital's classical transparent dressing, and were followed daily for any infectious and non-infectious complications. Complications were graduated for severity by an independent international multicentre multidisciplinary panel of practitioners using a Delphi process. RESULTS: We included 628 patients, 2214 catheters (873 PVCs, 630 CVCs, 512 ACs and 199 HDCs and PACs) and 4836 dressings. Overall incidence rate was of 60.9/1000 catheter-days. The most common complication was dysfunction (34.6/1000 catheter-days), mainly for PVCs (16/1000 catheter-days) and ACs (12.9/1000 catheter-days). Infectious complications incidence rate in CVCs and ACs was of 14.5/1000, mostly due to colonization (14.2/1000 catheter-days). Thrombosis incidence was of 3.8/1000 catheter-days with severe and very severe complications in 16 cases (1.8/1000 catheter-days) and one thrombosis-related death. 3M™ IV Advanced dressing did not decrease the rate of catheters with at least a minor complication [57.37/1000 vs. 57.52/1000 catheter-days, HR 1.03, CI (0.84-1.27), p = 0.81]. Incidence rates for each single complication remained equivalent: infectious [HR 0.93 (0.62-1.40), p = 0.72], deep thrombosis [HR 0.90 (0.39-2.06), p = 0.80], extravasation and phlebitis [HR 1.40 (0.69-2.82), p = 0.35], accidental removal [1.07 (0.56-2.04), p = 0.84] and dysfunction [HR 1.04 (0.80-1.35), p = 0.79]. CONCLUSION: The ADVANCED study showed the overall risk of complications to intravascular catheters in ICU patients being dysfunction, infection and thrombosis. The 3M™ IV Advanced dressing did not decrease complication rates as compared to standard dressings.
Authors: J F Timsit; F L'Hériteau; A Lepape; A Francais; S Ruckly; A G Venier; P Jarno; S Boussat; B Coignard; A Savey Journal: Intensive Care Med Date: 2012-07-14 Impact factor: 17.440
Authors: J L González López; A Arribi Vilela; E Fernández del Palacio; J Olivares Corral; C Benedicto Martí; P Herrera Portal Journal: J Hosp Infect Date: 2013-12-01 Impact factor: 3.926
Authors: Yanfeng Wang; Chanjuan Cui; Xin Liu; Lei Deng; Ke Yang; Bin Li; Jie Xue; Junying Xie; Wei Cui Journal: Thorac Cancer Date: 2022-05-13 Impact factor: 3.223
Authors: Yvan Fleury; Diego Arroyo; Caroline Couchepin; Helia Robert-Ebadi; Marc Righini; Johannes A Lobrinus; Bara Ricou; Nathalie Delieuvin Schmitt; Angèle Gayet-Ageron Journal: Intensive Care Med Date: 2018-04-02 Impact factor: 17.440
Authors: Amanda Corley; India Lye; Jayshree D Lavana; Abhilasha Ahuja; Chris M Anstey; Paul Jarrett; Emma Haisz; Rachael Parke; Vincent Pellegrino; Hergen Buscher; John F Fraser Journal: BMJ Open Date: 2019-07-10 Impact factor: 2.692
Authors: Pedro Parreira; Beatriz Serambeque; Paulo S Costa; Lisete S Mónico; Vânia Oliveira; Liliana B Sousa; Fernando Gama; Rafael A Bernardes; David Adriano; Inês A Marques; Luciene M Braga; João Graveto; Nádia Osório; Anabela Salgueiro-Oliveira Journal: Int J Environ Res Public Health Date: 2019-09-08 Impact factor: 3.390